MAVS and cancer: We predict that ADAR1 inhibitors would be very effective therapeutics for cancer treatment because they will interfere with two completely different pro-oncogenic ADAR1 functions: suppression of MDA5-MAVS-IFN signaling by the cytoplasmic ADAR1p150 and maintenance of telomere stability in telomerase-reactivated cancer cells by the nuclear ADAR1p110.